SEC-sourced researchBeta
DFPH
Starling Oncology, Inc.
Company comparison ↗
Data passport
- CIK
- 0001799191
- Exchange
- OTC
- Business activity
- — · SIC 8011
- Financial inputs
- 6/6
- Filing date
- Sep 2, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 393,412,000.0000 | Mar 12, 2026 |
| December 2025 | 502,729,000.0000 | Mar 12, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 502,729,000.0000 | -60,606,000.0000 | -24,587,000.0000 | 164,656,000.0000 | 180,376,000.0000 | Mar 12, 2026 |
| December 2024 | 393,412,000.0000 | -64,663,000.0000 | -26,538,000.0000 | 172,717,000.0000 | 169,128,000.0000 | Mar 12, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $502.73M | December 2025 | Mar 12, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $393.41M | December 2024 | Mar 12, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$60.61M | December 2025 | Mar 12, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$24.59M | December 2025 | Mar 12, 2026 | 10-K |
| Total assetsAssets | $164.66M | December 2025 | Mar 12, 2026 | 10-K |
| Total liabilitiesLiabilities | $180.38M | December 2025 | Mar 12, 2026 | 10-K |